Sholl, Lynette M. http://orcid.org/0000-0002-9532-9735
Halmos, Balazs http://orcid.org/0000-0001-7548-8360
Article History
Received: 6 May 2022
Revised: 16 August 2022
Accepted: 19 August 2022
First Online: 5 September 2022
Competing interests
: LMS and BH have disclosed no relevant conflicts of interest with the content of this editorial. LMS discloses research funding from Genentech, Bristol Myers Squibb (to institution), consulting fees from Genentech, Eli-Lilly (to institution) and consulting fees from AstraZeneca, GV20 Therapeutics (to LMS). BH discloses research funding from Boehringer-Ingelheim, Astra-Zeneca, Merck, Bristol Myers Squibb, Advaxis, Amgen, AbbVie, Daiichi, Pfizer, GSK, Beigene and Janssen (to institution) and consulting fees from Astra Zeneca, Boehringer-Ingelheim, Apollomics, Janssen, Takeda, Merck, Bristol Myers Squibb, Genentech, Pfizer, TPT, Arcus and Veracyte (to BH).
Free to read: This content has been made available to all.